{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:04Z","timestamp":1791288544417,"version":"4.3.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.neurol.2011.06.003","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T17:27:02Z","timestamp":1321637222000},"page":"930-937","source":"Crossref","is-referenced-by-count":5,"title":["Avanc\u00e9es dans le traitement pharmacologique des douleurs neuropathiques"],"prefix":"10.1016","volume":"167","author":[{"given":"N.","family":"Attal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2011.06.003_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejpain.2011.03.005","article-title":"Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome?","volume":"15","author":"Attal","year":"2011","journal-title":"Eur J Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0010","doi-asserted-by":"crossref","first-page":"1113-e88","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on pharmacological treatment of neuropathic pain, 2009\u00a0revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.pain.2008.01.006","article-title":"Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?","volume":"138","author":"Attal","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0020","first-page":"1102","article-title":"NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0025","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-5491.2009.02806.x","article-title":"Amitriptyline versus pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial","volume":"26","author":"Bansal","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.neurol.2011.06.003_bib0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pain.2010.04.013","article-title":"The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with lumbosacral radiculopathy","volume":"150","author":"Baron","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0040","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1\u00a0to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2011.06.003_bib0045","series-title":"Les douleurs neuropathiques","author":"Bouhassira","year":"2007"},{"key":"10.1016\/j.neurol.2011.06.003_bib0050","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pain.2008.11.009","article-title":"5-HT7\u00a0receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice","volume":"141","author":"Brenchat","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0060","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2011.06.003_bib0065","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABA A receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2011.06.003_bib0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pain.2010.06.019","article-title":"The evidence for pharmacological treatment of neuropathic pain","volume":"150","author":"Finnerup","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nurt.2010.05.016","article-title":"Targeting astrocyte signaling for chronic pain","volume":"7","author":"Gao","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2011.06.003_bib0085","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa042580","article-title":"Morphine, gabapentin, or their combination for neuropathic pain","volume":"352","author":"Gilron","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2011.06.003_bib0090","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(09)61081-3","article-title":"Nortritpyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial","volume":"374","author":"Gilron","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2011.06.003_bib0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1212\/01.wnl.0000275528.01263.6c","article-title":"Clinical trial outcome in neuropathic pain: relationship to study characteristics","volume":"70","author":"Katz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2011.06.003_bib0100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/dc10-1793","article-title":"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial","volume":"34","author":"Kaur","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neurol.2011.06.003_bib0105","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jpain.2009.09.019","article-title":"A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers","volume":"11","author":"Kennedy","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0110","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.pain.2010.12.023","article-title":"Safety and efficacy of pregabalin in patients with central post-stroke pain","volume":"152","author":"Kim","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/978-3-540-79090-7_17","article-title":"Future treatment strategies for neuropathic pain","volume":"194","author":"Marchand","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0120","unstructured":"Martinez V, Attal N, Bouhassira D, Lanteri-Minet D. Douleurs neuropathiques\u00a0: diagnostic, \u00e9valuation, traitement. Recommandations de la SFETD. Neurologies 2010."},{"key":"10.1016\/j.neurol.2011.06.003_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrn2533","article-title":"Pathological and protective roles of glia in chronic pain","volume":"10","author":"Milligan","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2011.06.003_bib0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/AJP.0b013e31802b582f","article-title":"Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study","volume":"23","author":"Portenoy","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","article-title":"Botulinum toxin a induces direct analgesic effects in neuropathic pain: a double blind placebo controlled study","volume":"64","author":"Ranoux","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.neurol.2011.06.003_bib0150","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1212\/01.wnl.0000314647.35825.9c","article-title":"NGX-4010\u00a0C107\u00a0Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2011.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jpainsymman.2009.11.316","article-title":"NGX-4010\u00a0C118\u00a0Study Group. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain","volume":"39","author":"Simpson","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.neurol.2011.06.003_bib0160","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2011.06.003_bib0170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pain.2010.09.005","article-title":"Duloxetine in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen","volume":"152","author":"Vranken","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2011.06.003_bib0175","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","article-title":"Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia","volume":"11","author":"Xiao","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.neurol.2011.06.003_bib0180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.21542","article-title":"Beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain","volume":"65","author":"Yalcin","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2011.06.003_bib0185","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378711003729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378711003729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T05:55:48Z","timestamp":1543384548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378711003729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0035378711003729"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2011.06.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}